Nexus Pharmaceuticals, Inc. v. Quva Pharma, Inc., et al
| QUVA PHARMA, INC. and QUVA PHARMA HOLDINGS, INC. |
| NEXUS PHARMACEUTICALS, INC. |
| 20-56160 |
| November 4, 2020 |
| U.S. Court of Appeals, Ninth Circuit |
| Other |
Opinions
We have the following opinions for this case:
| Description |
|---|
| NEXUS PHARMACEUTICALS, INC. V. QUVA PHARMA, INC., ET AL |
Docket Report
RSS Track this Docket
This docket was last retrieved on December 21, 2020. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 14 Filed clerk order (Deputy Clerk: SSR): The court has received appellants notice at Docket Entry No. [ # 11 ]. The motion to expedite at Docket Entry No. [ # 4 ] is deemed withdrawn. Appellants opposed motion (Docket Entry No. [ # 12 ]) to consolidate is denied. Nos. 20-56158, 20-56160, and 20-56227 will proceed separately but will be calendared before the same panel that will consider the merits of these appeals. The opening brief is now due January 25, 2021. The answering brief is due February 24, 2021. The optional reply brief is due within 21 days after service of the answering brief. [11934852] (OC) [Entered: 12/21/2020 11:54 AM] |
| Filing 13 Filed (ECF) Appellees Quva Pharma Holdings, Inc. and Quva Pharma, Inc. response opposing motion ([ # 12 ] Motion (ECF Filing), [ # 12 ] Motion (ECF Filing)). Date of service: 12/11/2020. [11924807] [20-56160] (Perloff, Saul) [Entered: 12/11/2020 03:12 PM] |
| Filing 12 Filed (ECF) Appellant Nexus Pharmaceuticals, Inc. Motion to consolidate cases 20-56158, 20-56160, and 20-56227. Date of service: 12/07/2020. [11917858] [20-56160] (Mock, Matthew) [Entered: 12/07/2020 05:31 PM] |
| Filing 11 Filed (ECF) Appellant Nexus Pharmaceuticals, Inc. Motion to strike whole of motion to expedite. Date of service: 11/30/2020. [11911046] --[COURT ENTERED FILING to correct entry [10] .] (TYL) [Entered: 12/01/2020 12:40 PM] |
| Filing 10 COURT DELETED INCORRECT ENTRY. Notice about deletion sent to case participants registered for electronic filing. Correct Entry: [ # 11 ]. Original Text: Filed (ECF) Appellant Nexus Pharmaceuticals, Inc. Correspondence: Notice of Withdrawal of Motion to Expedite Briefing on Appeal (Dkt. No. 4). Date of service: 11/30/2020 [11909750] [20-56160] (Mock, Matthew) [Entered: 11/30/2020 03:13 PM] |
| Filing 9 Filed (ECF) Appellant Nexus Pharmaceuticals, Inc. reply to response (). Date of service: 11/24/2020. [11905022] [20-56160] (Mock, Matthew) [Entered: 11/24/2020 11:32 AM] |
| Filing 8 Filed (ECF) Appellees Quva Pharma Holdings, Inc. and Quva Pharma, Inc. response to motion ([ # 4 ] Motion (ECF Filing), [ # 4 ] Motion (ECF Filing)). Date of service: 11/23/2020. [11903774] [20-56160] (Perloff, Saul) [Entered: 11/23/2020 02:40 PM] |
| Filing 7 Added Attorney(s) Saul Perloff for party(s) Appellee Quva Pharma Holdings, Inc. and Appellee Quva Pharma, Inc., in case 20-56160. [11895925] (QDL) [Entered: 11/17/2020 01:13 PM] |
| Filing 6 Filed (ECF) notice of appearance of Saul Howard Perloff (Norton Rose Fulbright US LLP, 111 W. Houston Street, Suite 1800, San Antonio, Texas 78205) for Appellees Quva Pharma Holdings, Inc. and Quva Pharma, Inc.. Date of service: 11/17/2020. (Party was previously proceeding with counsel.) [11895916] [20-56160] (Perloff, Saul) [Entered: 11/17/2020 01:10 PM] |
| Filing 5 MEDIATION ORDER FILED: By 11/23/2020, counsel to email Circuit Mediator regarding settlement potential. Include Ninth Circuit case number in subject line. This communication will be kept confidential, if requested, and should not be filed with the court. The existing briefing schedule remains in effect. SEE ORDER FOR DETAILS. [11895837] (LW) [Entered: 11/17/2020 12:24 PM] |
| Filing 4 Filed (ECF) Appellant Nexus Pharmaceuticals, Inc. Motion to expedite case. Date of service: 11/16/2020. [11894507] [20-56160] (Mock, Matthew) [Entered: 11/16/2020 03:04 PM] |
| Filing 3 The Mediation Questionnaire for this case was filed on 11/12/2020. To submit pertinent confidential information directly to the Circuit Mediators, please use the following # link . Confidential submissions may include any information relevant to mediation of the case and settlement potential, including, but not limited to, settlement history, ongoing or potential settlement discussions, non-litigated party related issues, other pending actions, and timing considerations that may impact mediation efforts.[11891432]. [20-56160] (AD) [Entered: 11/12/2020 06:44 PM] |
| Filing 2 Filed (ECF) Appellant Nexus Pharmaceuticals, Inc. Mediation Questionnaire. Date of service: 11/12/2020. [11891269] [20-56160] (Mock, Matthew) [Entered: 11/12/2020 04:56 PM] |
| Filing 1 DOCKETED CAUSE AND ENTERED APPEARANCES OF COUNSEL. SEND MQ: Yes. The schedule is set as follows: Appellant Nexus Pharmaceuticals, Inc. Mediation Questionnaire due on 11/12/2020. Appellant Nexus Pharmaceuticals, Inc. opening brief due 01/04/2021. Appellees Quva Pharma Holdings, Inc. and Quva Pharma, Inc. answering brief due 02/03/2021. Appellant's optional reply brief is due 21 days after service of the answering brief. [11881563] (JBS) [Entered: 11/04/2020 10:31 AM] |
Access additional case information on PACER
Access the Case Summary and Docket Report to access additional information about this case on the U.S. Court's PACER system. A subscription to PACER is required.
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
